United Therapeutics(NASDAQ) UTHR

United Therapeutics Corporation helps people with rare lung diseases. It creates medicines and devices to help patients breathe more easily. The company also works on making new organs for human transplants.

What's in the Medicine Cabinet?

• Tyvaso: Inhaled treprostinil solution used to treat high blood pressure in the lung arteries and lung scarring.
• Remodulin: Continuously infused treatment for patients with high blood pressure in the lung arteries, delivered via specialized pumps.
• Orenitram: Oral tablet version of treprostinil designed to boost exercise capacity for lung patients.
• Unituxin: Monoclonal antibody used to treat high-risk neuroblastoma, which is a rare type of cancer.
• Adcirca: Oral tablet for lung artery hypertension sold under a license that expires on Dec. 31, 2026.

Scaling Up Through Strategic Moves

• Acquired IVIVA Medical in October 2023 to develop manufactured kidney alternatives that use a patient's own cells.
• Purchased Miromatrix Medical in December 2023 to focus on engineered liver and kidney products for organ failure.
• Acquired Thymmune Therapeutics in July 2026 to develop therapies that restore immune function through the thymus gland.
• Entered a collaboration with Robinson Helicopter Company in October 2024 to develop zero-emission helicopters for organ delivery.

Engineering the Future of Transplants

United Therapeutics operates as a public benefit corporation, meaning it balances shareholder interests with the goal of expanding transplantable organ supplies. The company uses 3D printing and gene editing to create engineered organs and organ alternatives, such as the UKidney and UHeart.

Checking the Financial Vitals

• Total revenues were $783.3 million for the three months ended June 30, 2026, down 2% year over year.
• Net cash provided by operating activities was $776.9 million for the six months ended June 30, 2026, up 19% year over year.
• Cash and marketable investments totaled $3.8 billion as of June 30, 2026, down 19% from Dec. 31, 2025.
• Share repurchases reached $1.5 billion in March 2026 through two accelerated agreements with Citibank.
• Effective income tax rate was 12% for the six months ended June 30, 2026, compared to 24% for the same period in 2025.

The Evolution of Care

United Therapeutics has transitioned from a biotechnology firm focused on rare lung diseases to a leader in manufactured organ technologies. Its ongoing expansion into xenotransplantation and 3D organ printing highlights a long-term shift toward solving global organ shortages.